DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

摘要: BACKGROUND Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit chemotherapy. METHODS We used immunohistochemical analysis to determine expression excision repair cross-complementation group 1 (ERCC1) protein in operative specimens cancer. The had been enrolled International Lung Cancer Trial, thereby allowing a comparison effect adjuvant on survival, according ERCC1 expression. Overall was analyzed Cox model adjusted for and pathological factors. RESULTS Among 761 tumors, positive 335 (44%) negative 426 (56%). A from associated absence (test interaction, P=0.009). chemotherapy, as compared observation, significantly prolonged ERCC1-negative tumors (adjusted hazard ratio death, 0.65; 95% confidence interval [CI], 0.50 0.86; P=0.002) not ERCC1-positive 1.14; CI, 0.84 1.55; P=0.40). who did receive those survived longer than 0.66; 0.49 0.90; CONCLUSIONS Patients cancer appear whereas do not.